

CURRICULUM VITAE (abbreviated)

Name: Dr Susana Nabina Banerjee MBBS MA PhD FRCP

Address: The Royal Marsden NHS Foundation Trust
Chelsea and Sutton sites:
Fulham Rd Downs Rd
Chelsea Sutton
London Surrey
SW3 6JJ SM2 5PT
UK UK

Present appointment:

Nov 2011-present Consultant Medical Oncologist- Gynaecological Cancers
The Royal Marsden NHS Foundation Trust, Chelsea and Sutton
Mar 2012-present Research Lead Gynaecology Unit
The Royal Marsden NHS Foundation Trust, Chelsea and Sutton
Oct 2017-present Honorary Faculty, Team Leader Gynaecological Cancers (Systemic Therapy and Clinical Trials)
Institute of Cancer Research

Previous appointment:

Jun 2015-Sept 2017 Associate Honorary Faculty (Senior Lecturer), Institute of Cancer Research
Sep 2004-Sep 2005 Specialist Registrar in Medical Oncology
Sep 2009-Sep 2011 The Royal Marsden Hospital, London, UK

Education:

2005-2009 Institute of Cancer Research (ICR), University of London
1997- 2000 Royal Free and University College Medical School, London
1994-1997 St. John's College, Cambridge University

Qualifications:

2017 FRCP (Fellow of Royal College of Physicians)
2010 Postgraduate Diploma in Oncology
(Institute of Cancer Research, University of London)
2009 PhD (Institute of Cancer Research, University of London)
2003 MRCP (UK) (Royal College of Physicians)
2001 MA (Cantab.) (Cambridge University)
2000 MBBS (University of London)
Distinctions in Medicine, Surgery, Pathology, Pharmacology and Obstetrics & Gynaecology

University of London Gold Medal Finalist (*proxime accessit*)

1997 BA Hons (Cantab.) Physiology 1st Class (Cambridge University)
1996 Medical and Veterinary Sciences Tripos 1st Class (Cambridge University)

Prizes and Awards

2019 Honorary plaque, Institute of Molecular Medicine and Biomedical Research, Athens
2012 International Gynaecologic Cancer Society Young Doctors' Summit Award
2009 Pfizer BOA Young Investigator Award- highly commended
2009 Sir Antony Driver Prize
(for outstanding research, education and charity interaction at Breakthrough Breast Cancer
Centre, Institute of Cancer Research)
2009 McElwain Prize (Association of Cancer Physicians)
(for outstanding cancer research)
2009 IMPAKT (European Society for Medical Oncology) travel award
2007 San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Scholars award
2005 Avon Breast Cancer Crusade Clinical Fellowship
2000 University Gold Medal finalist (*proxime accessit*)
2000 E.D. Blunt Prize in General Medicine
2000 Glynn Morgan Prize in Chest Medicine and Cardiology

	Leica Prize in Histopathology
	Esther Frances White Memorial Prize for distinction in MBBS
1998	Glaxo-Wellcome and Blackwell Science Book Prize (for excellent academic performance in the first clinical year)
1997	Rolleston Scholarship for achieving 1 st Class in B.A (Hons) Northcott Prize for Preclinical Medicine
1996	Rolleston Scholarship for achieving 1 st Class in 2 nd MB Tripos College Prize for Pharmacology

Research Experience- Basic Science Research

PhD (biochemistry) Dec 2009

Sept 2005- March 2009 Breakthrough Breast Cancer Research Centre,
Institute of Cancer Research, University of London
Supervisor: Prof Mitch Dowsett

Funding Award: The Avon Breast Cancer Crusade Fellowship

Title: 'The interaction between vascular endothelial growth factor and oestrogen signalling in breast cancer'

Research Experience- Clinical Research

I have been/am Chief Investigator (CI) of 8 academic studies and local (Royal Marsden) Principal Investigator of 18 National Cancer Research Network trials portfolio (investigator-initiated) studies.

I am/have been Global Co-ordinating Investigator (CI) for 2 international trials; UK CI of 8 international trials and local (Royal Marsden) Principal Investigator (PI) of 36 commercial trials- 23 of which have adoption on to the NIHR CRN trials portfolio.

Research Experience- Grants

Lead Applicant

- 2013 Janssen Educational Grant (Lead: Dr Susana Banerjee) for CORAL trial (phase II multi-centre trial of abiraterone in ovarian cancer). Academic sponsored trial (Institute of Cancer Research)
CRUK Clinical Trials Awards and Advisory Committee CTAAC endorsement
- 2013 Royal Marsden/ICR Biomedical Research Centre grant for 2 years to support the CORAL study (translational and clinical)
- 2015 Astrazeneca Educational Grant (Lead: Susana Banerjee) for OCTOPUS (Arm 1) trial
A Randomised, Phase II Umbrella Trial of Weekly Paclitaxel v Novel Agent Arms in Platinum-Resistant Ovarian Cancer (Arm 1 vistusertib/AZD2014)
Academic sponsored trial (AZ NCRN alliance, NHS Greater Glasgow and Clyde/University of Glasgow) NIHR CRN portfolio trial
CRUK Clinical Trials Awards and Advisory Committee CTAAC endorsement
- 2016 London Cancer Alliance (LCA)/NIHR-Biomedical Research Centre
Improving outcomes in older women with ovarian cancer
1 year clinical fellow for higher degree, ICR MD
- 2019 Astrazeneca educational grant (Externally Sponsored Scientific Research) for ATARI trial
ATARI- A phase II international trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss
Academic sponsored trial (Institute of Cancer Research) NIHR CRN portfolio trial, GCIG/ENGOT/NCRI-led trial
CRUK Clinical Trials Awards and Advisory Committee CTAAC endorsement

- 2019 TESARO Educational Grant (Lead: Susana Banerjee) MONITOR: UK: An Observational multi-centre study of Maintenance Niraparib in Patients with Platinum-sensitive Ovarian Cancer
Academic sponsored trial (Royal Marsden) NIHR CRN portfolio trial
- 2019 Wellbeing of Women Research Project Grant
Improving outcomes in older women: Feasibility of frailty assessment and implementation of protocol-led geriatric interventions in women over the age of 70 with relapsed epithelial ovarian cancer in the oncology clinic (FAIR-O)
Academic sponsored trial (Royal Marsden) NIHR CRN portfolio trial

Co-applicant

- 2012 Wellcome Strategic Award (Role co-applicant: Susana Banerjee; Lead Prof Nazneen Rahman) Using Genetics in Mainstream Medicine to deliver Personalised Care for Cancer Patients
- 2017 CRUK funding award
A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs cisplatin for standard Risk paediatric and adult patients with germ cell tumours AGCT1531
- 2017 Innovate UK: Biomedical Catalyst- Early Stage Award
Project Title: Comprehensive blood counts in a handheld device: home monitoring in chemotherapy.
- 2019 Innovate UK Biomedical Catalyst- Late Stage Award
Project Title: Affinity- Home blood count monitoring for personalised delivery of cancer therapy and care. includes funding for Academic sponsored study (Royal Marsden, Chief Investigator: Susana Banerjee MATCH)

Research Experience- Leadership

Trial Steering Committee member- 3 International industry-sponsored trials, 1 academic (investigator-initiated) trial

Trial Management Group member- 5 academic (investigator-initiated), NIHR CRN trials

Research/Scientific Committee leadership roles

2015,2016 2019 and 2020	ESMO congress Scientific Committee member (Gynaecological Cancers)
2018	ESMO Asia Scientific Programme Committee Co-Chair, Singapore
2017-2018	ESMO congress 2018 Scientific Committee Track Chair Gynaecological Cancers
2018	International SCCOHT Consortium member
2015-2021	ESMO Gynaecological Cancers Faculty member (term renewed)
2015	European Cancer Congress, Young Oncologists Track Chair
2014-present	NCRI Clinical Studies Group (CSG), Gynaecological Cancer member
Sept 2012-present	NCRN ovarian subgroup committee member
Mar 2015-2018	NCRI cervical subgroup committee member
Nov 2017	Gynaecologic Cancer Intergroup (GCIG) NCRI representative, Vienna
Jun 2017	Gynaecologic Cancer Intergroup (GCIG) NCRI/SGCTG representative, Chicago
Oct 2016	Gynaecologic Cancer Intergroup (GCIG) NCRI representative, Lisbon
Jun 2017-present	ENGOT phase I/II NCRI representative
Jun 2017-present	EORTC Gynaecological Cancer Group NCRI representative
Mar 2014-Mar 2017	European Organisation for Research and Treatment of Cancer (EORTC) Gynaecological Cancers Group Steering Committee member
2016-present	Malignant Germ Cell International Collaboration (MAGIC) member adult ovarian UK representative
2014-present	South London Research Network- Gynaecological Cancers lead
2013-2016	London Cancer Alliance/Royal Marsden Cancer Vanguard- Gynaecological Cancers Research lead
2011-2016	Member of Royal Marsden Committee for Clinical Research (CCR)

2014-present Ovarian Cancer Association Consortium (OCAC) member
 2010- 2011 FLIMS (ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research
 Alumni Club steering committee member

Training

Higher Degree Supervisory roles:

MD clinical fellow, Primary Supervisor

Funding: London Cancer Alliance/Biomedical Research Centre fellowship award and Lady Garden Charity

Title: Improving outcomes for older women with gynaecological malignancies

International Society of Geriatric Oncology (SIOG) Young Investigator Award 2018

PhD clinical fellow, Associate Supervisor

Funding: ICR CRUK/Wellcome Trust Clinical Research Fellowship 2018

Primary Supervisor: Prof Chris Lord (ICR)

Sept 2018- present

Title: 'Improving the clinical management of gynaecological cancers using synthetic lethal approaches'

PhD clinical fellow, Associate Supervisor

Primary Supervisor: Dr Rachael Natrajan (ICR)

2019- PhD Award

Title: Identification of Novel Therapeutic Strategies for ARID1A-deficient Ovarian Clear Cell Carcinomas

PhD student, Associate Supervisor

Primary Supervisor: Mark Cropley University of Surrey (2016-2018)

PhD awarded October 2018

Title: Cancer Survivorship: The development of a psychoeducational intervention to improve quality of life in women after treatment for gynaecological cancers

MD clinical fellow, Associate Supervisor

Primary Supervisor: Prof Nazneen Rahman (ICR)

Funding: Wellcome (first year, Royal Marsden Gynaecological Cancers Fund)

Title: 'Development and optimisation of germline cancer gene testing for ovarian cancer'

PhD clinical fellow, Associate Supervisor

Primary Supervisor: Prof Alan Ashworth

Thesis title: Identification of therapeutic targets for ovarian clear cell carcinoma

I am also supervising clinical fellows (total to date 11) and trainees attached to the Royal Marsden gynaecological unit on a variety of clinical research projects.

Other Training roles:

2015-2019 ICR Mel Greaves Science Writing Prize judging panel

2017 ESMO/ESO Medical Students Course, lecturer, Valencia

2016 Co-author of ESMO/ASCO recommendations for a Global Curriculum in medical oncology

2015 and 2016 Co-chair of the ESMO/ESO Medical Students Course, Valencia

2015 European Cancer Congress Young Oncologists Workshop:

How to Avoid Burnout -Achieving Optimal Work-Life Balance

2015 European Cancer Congress Mentorship session organiser

2015 European Cancer Congress

How to Improve Cancer Training and Career Planning? Chair

May 2013-present ESMO Fellowship Host Institute (Royal Marsden) contact

Dec 2012-present European School of Oncology (ESO) Fellowship Host institute (Royal Marsden) contact

Leadership and Clinical Research Development Programmes

ESMO Leaders Generation Programme 2019- Faculty and discussant at Women for Oncology session
 ESMO Leaders Generation Programme 2018- Faculty and discussant at Women for Oncology session
 ESMO Leaders Generation Programme 2018- participant in Leadership Skills Workshop
 Athena Swan scheme (promoting women in science), Institute of Cancer Research (2015,2016)
 ESMO Leaders Generation Programme 2016- competitive selection (June 2016)
 Gynaecological Cancer Academy (GCA)- an educative programme (2 years) aiming to nurture and develop the next generation of leaders in gynaecological oncology (2015, 2016)
 ECCO/AACR/EORTC/ESMO Methods in Clinical Research Workshop, Flims, Switzerland (2010) (*Competitive selection*)

Selected Invited Educational Lectures (speaker and chair roles)

Mar 2019	ESMO Latin America Summit (Sao Paulo) Gynaecological Cancers, Chair and speaker
Nov 2018	ESMO Asia (Singapore) Presidential opening session- Scientific Chair address
Nov 2018	ESMO Asia (Singapore) ESMO/ESGO Ovarian Cancer Consensus summary, speaker
Nov 2018	ESMO Asia (Singapore) Chair of Proffered Paper Session
Nov 2018	Pathway to Independence Biomedical Research Centre event, Cambridge support early career clinical academics (my clinical academic career)
Oct 2018	ESMO congress (Munich) Invited Discussant, Chair of Proffered Paper Session gynaecological cancers
Oct 2018	ESMO congress (Munich) Special Symposium: Tumour heterogeneity in gynaecological cancers Chair
Oct 2018	Pelvic Cancers National Day, The Royal Marsden, lecturer
July 2018	British Gynaecological Cancer Society, Industry Symposium, London(Tesaro) Niraparib maintenance therapy in clinical practice, Chair and speaker
Jun 2018	Institute of Cancer Research conference- Novel therapeutics in ovarian cancer
Jun 2018	Cultivating Primary Resilience: Burnout Prevention on a Larger Scale, ASCO, Chicago Chair and speaker
April 2018	ESMO Middle East Summit, Dubai, Gynaecological Cancers, Chair and speaker
Mar 2018	Royal Marsden/ICR 5th Symposium on Molecular Pathology in Oncology Genetics in Ovarian Cancer
Sept 2017	ESMO congress (Madrid) ESMO-IPOS symposium: Working together to prevent professional burnout and improve patient care, Chair and speaker
Sept 2017	ESMO congress (Madrid)Special Symposium Immunotherapy and targeted therapies in gynaecological Malignancies, Chair
Sept 2017	ESMO congress (Madrid)- How to integrate PARP inhibitors into clinical practice, speaker
Sept 2017	ESMO congress (Madrid)- Prevalence and prevention of burn-out in young oncologists, speaker
April 2017	ESMO Preceptorship in Ovarian Cancer (Prague), speaker 3 sessions (BRCA, first line therapy, older women)
Oct 2016	ESMO congress (Copenhagen)- Young Oncologist Forum Professional development and communication skills, Chair
Oct 2016	Association of Cancer Physicians UK Trainees' Meeting- lecturer, Burnout
Jun 2016	Ovarian Cancer, The Leah Lederman lecture and Annual General Meeting Royal Society of Medicine, London, Chair
April 2016	Keynote Lecturer- ANZGOG: Australia New Zealand Gynaecological Oncology Group Translational Research- the experience and perspectives of a clinical trialist
April 2016	EORTC Gynaecological Cancers Scientific Meeting (Madrid), speaker PARP Inhibitors in Recurrent Ovarian Cancer
Sept 2015	European Cancer Congress (Vienna) Scientific Symposium, speaker Treatment opportunities for homologous recombination deficiency (PARP Inhibitors), speaker
Sept 2015	European Cancer Congress (Vienna)-speaker Implementation of widespread BRCA testing - the oncologist's perspective
July 2015	British Gynaecological Cancer Society, Industry Symposium, London(Astrazeneca) BRCA testing in ovarian cancer, speaker
Mar 2015	Association of Cancer Physicians, New UK Consultants' meeting- lecturer, Burnout
Sept 2014	ESMO congress (Madrid) Fellowships in Europe: Educational opportunities for Young Oncologists Speaker
Sept 2014	ESMO congress (Madrid) Industry Satellite Symposium (Astrazeneca)

- Speaker: BRCA-associated ovarian cancer: How to personalize first-line and subsequent therapies?
 June 2014 GP MIMs educational oncology programme day (Royal Marsden/CRUK), London
 Programme Chair, 2 lectures: symptoms of ovarian cancer and BRCA testing
 Sept 2013 Ovarian Cancer, The Leah Lederman lecture and Annual General Meeting
 Royal Society of Medicine, London, Chair
 Nov 2013 EORTC Gynaecological Cancers Scientific Meeting (Madrid), speaker
 New Agents in Cervical Cancer
 Sept 2013 European Cancer Congress (Amsterdam) PARP inhibitors in ovarian cancer, speaker

Selected Patient and Public Engagement Events

- Nov 2018 South East Cancer Help Centre Annual General Meeting
 Oct 2018 ESMO congress Press Conference, speaker (SOLO1 trial ovarian cancer)
 July 2018 Queensgate Girls' School Prize Giving
 (STEM: science, technology, engineering and mathematics promotion)
 Dec 2017 Metropolitan Police- talk Gynaecological Cancers and research, London
 May 2017 JP Morgan Womens' Event (Key Speaker), London
 Oct 2016 'Women of the Year' annual lunch- elected for achievements and contribution to society
 Oct 2015 Medscape Medical News- A Call for More Women Oncologists at the Podium
 Oct 2014 ESMO congress Press Conference, speaker (ESMO Burnout survey)
 Aug 2013 Target Ovarian Cancer- Research Advocates Training Day, London, speaker

Editorial Advisory Boards and Reviewer (peer-reviewed journals)

Nature Reviews Clinical Oncology

Cancer Treatment Reviews

International Journal of Gynaecologic Cancer

ESMO open

I have peer-reviewed manuscripts for journals including *New England Journal of Medicine*, *The Lancet*, *Clinical Cancer Research*, *Annals of Oncology* and *Therapeutic Advances in Medical Oncology*.

International Board/Steering Committee Membership

European Society of Medical Oncology (ESMO) Resilience Task Force, Chair (2019-present)

European Society of Medical Oncology (ESMO) Council (Feb 2019-present)

European Society of Medical Oncology (ESMO) Executive Board (Jan 2017 –Jan 2019)

European Organisation for Research and Treatment of Cancer (EORTC) Gynaecological Cancers Steering Committee (Mar 2014 - Mar 2016)

European Society of Medical Oncology (ESMO) Women for Oncology Committee (2015 -present)

European Society of Medical Oncology (ESMO) Young Oncologists' Committee (2010 -2016)

European Society of Medical Oncology (ESMO) Nominating Committee (2014-2015)

Publications

Thesis

December 2009 PhD (Institute of Cancer Research, University of London)

'The interaction between vascular endothelial growth factor and oestrogen signalling in breast cancer'

Published Meeting abstracts >50 (available on request)

Peer reviewed articles (†corresponding author)

27 first author; **29** last author; **34** corresponding author ;**100** total

H-index 29; citations 3326

100. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, **Banerjee S**, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. *Gynecol Oncol*. 2019 Mar;152(3):560-567.
99. Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, Li B, Ye F, Berchuck 9, Anton-Culver H, **Banerjee S**, Benitez J, Bjørge L, Brenton JD, Butzow R, Campbell IG, Chang-Claude J, Chen K, Cook LS, Cramer DW, DeFazio A, Dennis J, Doherty JA, Dork T, Eccles DM25, Velez Edwards D, Fasching PA, Fortner RT, Gayther SA, Giles GG, Glasspool RM, Goode EL, Goodman MT, Gronwald J, Harris HR, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Huntsman DG, Kar SP, Karlan BY, Kelemen LE, Kiemeny LA, Kjaer SK, Koushik A, Lambrechts D, Le ND, Levine DA, Massuger LFAG, Matsuo K, May T, McNeish IA, Menon U, Modugno F, Monteiro AN, Moorman PG, Moysich KB, Ness RB, Nevanlinna H, Olsson H, Onland-Moret NC, Park SK, Paul, Pearce CL, Pejovic T, Phelan CM66, Pike MC, Ramus SJ, Riboli E, Rodríguez-Antona C, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Shan K, Siddiqui N, Sieh W, Stampfer MJ, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Tworoger SS, Tyrer JP, Webb PM, Wentzensen N, White E, Willett WC, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. *Cancer Res*. 2018 Dec 17. pii: canres.2726.2018. doi: 10.1158/0008-5472.CAN-18-2726. [Epub ahead of print]
98. Orbegoso C, Murali K, **Banerjee S**. The current status of immunotherapy for cervical cancer. *Rep Pract Oncol Radiother*. 2018 Nov-Dec;23(6):580-588
97. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, **Banerjee S**, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2018 Oct 21. doi: 10.1056/NEJMoa1810858. [Epub ahead of print]
- †96. **Banerjee S**, Dafni U, Allen T, Arnold D, Curigliano G M.D, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. *ESMO Open*. 2018 Sep 21;3(6):e000422. doi: 10.1136/esmoopen-2018-000422.
95. Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, **Banerjee S**, Curigliano G M.D, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Report on the status of women occupying leadership roles in oncology. *ESMO Open*. 2018 Sep 21;3(6):e000423. doi: 10.1136/esmoopen-2018-000423. eCollection 2018.
94. Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, **Banerjee S**, Lichtman SM. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. *J Geriatr Oncol*. 2018 Oct 14. pii: S1879-4068(18)30314-X. doi: 10.1016/j.jgo.2018.10.008. [Epub ahead of print]
93. Heindl A, Khan AM, Rodrigues DN, Eason K, Sadanandam A, Orbegoso C, Punta M, Sottoriva A, Lise S, **Banerjee S**, Yuan Y. Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. *Nat Commun*. 2018 Sep 25;9(1):3917.
- †92. Murali K, **Banerjee S**. Let's address burnout in oncologists and reimagine the way we work. *Nat Rev Clin Oncol*. 2018 Sep 21. doi: 10.1038/s41571-018-0097-9.
- †91. Murali K, Makker V, Lynch J, **Banerjee S**. From Burnout to Resilience: An Update for Oncologists. *Am Soc Clin Oncol Educ Book*. 2018 May 23;(38):862-872.
90. Castellani F, Nganga EC, Dumas L, **Banerjee S**, Rockall AG. Imaging in the pre-operative staging of ovarian cancer. *Abdom Radiol (NY)*. 2018 Sep 19. doi: 10.1007/s00261-018-1779-6
- †89. Stewart J, George A, **Banerjee S**. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. *Expert Rev Anticancer Ther*. 2018 Aug 24:1-12
88. Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, **Banerjee S**, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR. Quality of life in patients with

- recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*. 2018 Jul 16. pii: S1470-2045(18)30333-4.
87. Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, **Banerjee S**, de Bono JS, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. *Ann Oncol*. 2018 Jul 17. doi: 10.1093/annonc/mdy245
- †86. Murali K, **Banerjee S**. Burnout in oncologists is a serious issue: What can we do about it? *Cancer Treat Rev*. 2018 Jul;68:55-61.
- †85. Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust AG, Lord CJ, **Banerjee S**, Natrajan R. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. *J Pathol Clin Res*. 2018 Apr 16. doi: 10.1002/cjp2.103. [Epub ahead of print] joint corresponding author
- †84. Oza A, Kaye S, Van Tornout J, Sessa C, Gore M, Naumann RW, Hirte H, Colombo N, Chen J, Gorla S, Poondru S, Singh M, Steinberg J, Yuen G, **Banerjee S**. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. *Gynecol Oncol*. 2018 Feb 14. pii: S0090-8258(18)30058-1. Do 10.1016/j.ygyno.2018.01.019. [Epub ahead of print]
83. Global cancer control: responding to the growing burden, rising costs and inequalities in access. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, **Banerjee S**, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. *ESMO Open*. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285.
82. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Moore KN, Vergote I, Oaknin A, Colombo N, **Banerjee S**, Oza A, Pautier P, Malek K, Birrer MJ. *Future Oncol*. 2018 Feb 9. doi: 10.2217/fon-2017-0646.
- †81. **Banerjee S**, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. *Ann Oncol*. 2018 Feb 1. doi: 10.1093/annonc/mdy023. [Epub ahead of print]
- †80. Orbegoso C, Marquina G, George A, **Banerjee S**. The role of Cediranib in ovarian cancer. *Expert Opin Pharmacother*. 2017 Oct;18(15):1637-1648.
- †79. Dolly SO, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, **Banerjee S**. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. *ESMO Open*. 2017 Apr 12;2(1):e000101. doi: 10.1136/esmoopen-2016-000101. eCollection 2017.
- †78. **Banerjee S**. Bevacizumab in cervical cancer: a step forward for survival. *Lancet*. 2017 Oct 7;390(10103):1626-1628.
- †77. Khalique S, and **Banerjee S**. Nintedanib in ovarian cancer. *Expert Opin Invest Drugs*. 2017 Jul 19. doi: 10.1080/13543784.2017.1353599. [Epub ahead of print] [Review]
76. Pujade-Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, **Banerjee S**, Liu J, Lowe E, Bloomfield R, Pautier P. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017; Sep;18(9):1274-1284
75. Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, **Banerjee S**, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. *Semin Oncol*. 2017 Jun;44(3):187-197.
74. George A, **Banerjee S**, Kaye S. Olaparib and somatic BRCA mutations. *Oncotarget*. 2017; 8(27):43598-43599. [Review]
- †73. George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, Kaye S, **Banerjee S**. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. *BMC Cancer*. 2017;17(1):456. doi: 10.1186/s12885-017-3440-0.
- †72. **Banerjee S**, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH. Professional burnout in european young oncologists: results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. *Ann Oncol*. 2017 Apr 25. doi: 10.1093/annonc/mdx196. [Epub ahead of print]
71. Rafii S, Gourley C, Kumar R, Geuna E, Ang JE, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, **Banerjee S**, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in

- germline BRCA1/2 mutated patients with advanced ovarian cancer. *Oncotarget*. 2017 Apr 10. doi: 10.18632/oncotarget.17005. [Epub ahead of print]
70. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCs study group., Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, **Banerjee SN** et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet*. 2017 May;49(5):680-691.
69. George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, **Banerjee SN**, Gore ME, de Bono JS, Kaye SB, Yap TA. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. *Eur J Cancer*. 2017;76:52-59.
- †68. McLachlan, J., Boussios, S., Okines, A., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor A, Lalondrelle S, Gore M, Kaye S, **Banerjee, S**. The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. *Clin Oncol*. (R Coll Radiol). 2016; doi:10.1016/j.clon.2016.10.002.
67. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, **Banerjee S**, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Taberero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). *ESMO Open*. 2016 Dec 7;1(6):e000107. [Review]
- †66. George A, Kaye S, **Banerjee S**. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. *Nat Rev Clin Oncol*. 2016 Dec 13. doi: 10.1038/nrclinonc.2016.191. [Review]
65. Friedlander M, **Banerjee S**, Mileskin L, Scott C, Shannon C, & Goh J. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. *Asia Pac J Clin Oncol*. 2016; 12(4), 323-331. doi:10.1111/ajco.12636 [Review]
64. Vergote I, **Banerjee S**, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo, N. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. *Eur J Cancer* 2016; 69, 127-134. [Review]
- †63. McLachlan J, George A, **Banerjee S**. The current status of PARP inhibitors in ovarian cancer. *Tumori*. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Review.
- †62. Dumas L, Ring A, Butler J, Kalsi T, Harari D, **Banerjee S**. Improving outcomes for older women with gynaecological malignancies. *Cancer Treat Rev*. 2016 Nov;50:99-108. doi: 10.1016/j.ctrv.2016.08.007. Epub 2016 Aug 29. Review.
61. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group. Carraway H, Lee Close J, Gilbert J, Bokemeyer C, Cervantes A, Lee Close J, Gilbert J, Ohe Y, Pless M, McGregor K, Fumassoli K, Candiani R, Bricalli G, Kenny T, Latino N, Cogo M, Pavinato V, Marchesi V, Awada A, **Banerjee S**, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Lee Close J, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Jennifer Markham M, Markman B, Mayerhoefer M, Meran JG, Michielin O, Charlotte Moser E, Mountzios G, Moynihan T, Nielsen T, Öberg K, Ohe Y, Palumbo A, Alessandro Peccatori F, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Taberero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. *Ann Oncol*. 2016;27(8):1378-81. doi: 10.1093/annonc/mdw239. [Review]
60. George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, **Banerjee S**, Hanson H, Rahman N. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. *Sci Rep*. 2016;6: 29506. doi: 10.1038/srep29506
- †59. Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, Rahman N, **Banerjee S**. The integration of BRCA testing into oncology clinics. *Br J Nurs*. 2016;25(12):690-4. doi: 10.12968/bjon.2016.25.12.690.
- †58. McLachlan J, Gore M, **Banerjee S**. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. *Pharmacogenomics*. 2016;17(12):1353-63. doi: 10.2217/pgs.16.24. Epub 2016 Jul 29 [Review]
- †57. Moschetta M, George A, Kaye SB, **Banerjee S**. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. *Ann Oncol*. 2016; Mar 31. pii: mdw142. [Epub ahead of print] [Review]
- †56. McLachlan J, **Banerjee S**. Olaparib for the treatment of epithelial ovarian cancer. *Expert Opin Pharmacother*. 2016 ;17(7):995-1003 [Review]

- †55. McLachlan J, Lima JP, Dumas L, **Banerjee S**. Targeted agents and combinations in ovarian cancer: where are we now? *Expert Rev Anticancer Ther.* 2016;16(4):441-54 [Review]
- †54. Boussios S, Attygalle A, Hazell S, Moschetta M, McLachlan J, Okines A, **Banerjee S**. Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. *Anticancer Res.* 2015;35(12):6713-22.
53. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. *Ann Oncol.* 2016;27(1):16-41. [Review]
52. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. *Int J Gynecol Cancer.* 2016;26(1):2-3. [Review]
51. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. *Radiother Oncol.* 2015 Dec;117(3):559-8 [Review]
50. Heath OM, van Beekhuizen HJ, Nama V, Kolomainen D, Nobbenhuis MA, Ind TE, Sohaib SA, Lofts FJ, Heenan S, Gore M, **Banerjee S**, Kaye SB, Barton DP. Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. *Thromb Res.* 2015 Nov 22. pii: S0049-3848(15)30206-1. doi: 10.1016/j.thromres.2015.11.030. [Epub ahead of print]
49. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D; EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A; kConFab Investigators, James PA, Bruinsma F, Campbell IG; Australia Ovarian Cancer Study Group, Broeks A, Schmidt MK, Hogervorst FB; HEBON, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, **Banerjee S**, Menon U, Tomlinson I et al. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. *J Natl Cancer Inst.* 2015;108(2)
48. Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, **Banerjee S**, Jackson D, Lord R, McCormack M, Hudson E, Reed N, Flubacher M, Jankowska P, Powell M, Dive C, West CM, Paul J. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCA): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncol.* 2015;16(15):1515-24
47. Lan C, Heindl A, Huang X, Xi S, **Banerjee S**, Liu J, Yuan Y. Quantitative histology analysis of the ovarian tumour microenvironment. *Sci Rep.* 2015;5:16317
- †*46. Seifert H, Georgiou A, Alexander H, McLachlan J, Bodla S, Kaye S, Barton D, Nobbenhuis M, Gore M, **Banerjee S**. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). *Gynecol Oncol.* 2015; Aug 26. pii: S0090-8258(15)30107-4. doi: 10.1016/j.ygyno.2015.08.015. [Epub ahead of print]
- †45. McLachlan J, **Banerjee S**. Pazopanib in ovarian cancer. *Expert Rev Anticancer Ther.* 2015;15(9):995-1005. [Review]
- †44. **Banerjee S**, & Stanway S. Problem solving in acute oncology. *Br J Cancer.* 2015; 113(12), 1744-1745. doi:10.1038/bjc.2014. [Review]
- †43. Nobbenhuis MA, Lalondrelle S, Larkin J, **Banerjee S**. Management of melanomas of the gynaecological tract. *Curr Opin Oncol.* 2014;26(5):508-13. [Review]
- †42. Della Pepa C and **Banerjee S**. Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. *OncoTargets and Therapy.* 2014; 7:1025-32. [Review]
41. Syrios J, **Banerjee S**, Kaye SB. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets - where are we now? *Anticancer Res.* 2014; 34(5):2069-77 [Review]
40. McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, **Banerjee S**, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. *Ann Oncol.* 2014;25(10):1988-95.
39. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, **Banerjee S**, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. *Gynecol Oncol.* 2014 Jul 10. pii: S0090-8258(14)01070-1. doi: 10.1016/j.ygyno.2014.06.029. [Epub ahead of print]
38. Califano R, Karamouzis MV, **Banerjee S**, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. *Lung Cancer.* 2014 Mar 16. pii: S0169-5002(14)00131-7. doi: 10.1016/j.lungcan.2014.03.010. [Epub ahead of print]
37. Thway L, Hazell S, **Banerjee S**, Fisher C. Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. *Case Rep Pathol.* 2014; 238545. doi: 10.1155/2014/238545. Epub 2014 Jan 22.

36. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, **Banerjee S**, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. *Clin Cancer Res* 2013;19(19):5485-93.
35. Jenkins V, Catt S, **Banerjee S**, Gourley C, Montes A, Solis-Trapala I, Monson K, Fallowfield L. Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study. *Br J Cancer*. 2013;108(11):2264-71.
34. Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, **Banerjee S**, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. *Eur J Cancer*, 2013; 49(6):1246-53
33. **Banerjee S**, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skaiels G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB. A multicenter, randomized trial of flat dosing versus inpatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. *Ann Oncol*, 2013;24(3):679-87
- †32. Miller RE, **Banerjee S**. The current state of pemetrexed in ovarian cancer. *Expert Opin Investig Drugs*. 2013; 22(9):1201-10.
31. **Banerjee S** and Gore M. Targeted Therapy for the management of ovarian cancer. *Scientific Impact paper no 12*. 2013; Royal College of Obstetricians and Gynaecologists. [Review]
30. Lopez J, **Banerjee S**, Kaye SB. New developments in the treatment of ovarian cancer -future perspectives. *Ann Oncol*. 2013 Dec; 24 Suppl 10:x69-x76. doi: 10.1093/annonc/mdt475. [Review]
29. **Banerjee S**, Gore M. Personalized therapy in gynecological cancer: a reality in clinical practice? *Curr Oncol Rep*. 2013;Jun;15(3):201-3. [Review]
28. **Banerjee S**, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. *Clin Cancer Res*. 2013; 19(5):961-8 [Review]
- †27. Chia, WK George, A, **Banerjee S**. Systemic treatment for recurrent epithelial ovarian cancer. *Expert Review of Obstetrics and Gynecology*. 2013; vol 8, Number 2, pp. 161-168(8) [Review]
26. **Banerjee S**, Kaye. Progression-free survival versus overall survival in ovarian cancer: where are we now? *Curr Oncol Rep*. 2012; 14(6):483-5. [Review]
- †25. Weigelt B and **Banerjee S**. Molecular targets and targeted therapeutics in endometrial cancer. *Curr Opin Oncol*. 2012; May epub ahead of print [Review]
24. **Banerjee S** and Kaye S. First-line bevacizumab for ovarian cancer—new standard of care? *Nat Rev Clin Oncol*. 2012; 9(4):194-6. [Review]
23. **Banerjee S**, Gore M. Recent advances in systemic treatments for ovarian cancer. *Cancer Imaging*. 2012; 12:305-9. [Review]
22. **Banerjee S** and Kaye S. PARP inhibitors in BRCA gene mutated ovarian cancer and beyond. *Current Oncology Reports*, 2011; 13(6):442-9. [Review]
21. **Banerjee S** and Kaye S. The role of targeted therapy in ovarian cancer. The ECCO-ESMO European Multidisciplinary Cancer Congress Education Book. *Eur J Cancer*. 2011; 47 Suppl 3 pp.S116-S130. [Review]
- †20. Stanway S and **Banerjee S**. MSc in oncology. *BMJ Careers*. 2011; 342:40 [Review]
- †19. **Banerjee S**. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. *Steroids*. 2011; 76(8):807-11. [Review]
18. Sanfilippo R, F Grosso F, Jones RL, **Banerjee S**, D'Incalci M, Raspagliesi F, Judson I, Casali PG. Role of trabectedin in the management of advanced uterine leiomyosarcomas. *Gynecol Oncol*. 2011; 123(3):553-6
17. **Banerjee S** and Smith IE. Management of small HER2-positive breast cancers. *Lancet Oncol*. 2010; 11:1193-9 [Review]
- †16. **Banerjee S**. Becoming a new consultant: how to make it work for you. *Clin Med*. 2010; 10, no 1: 41-2.
15. **Banerjee S**, Kaye S and Ashworth A. Making the best of PARP inhibitors in ovarian cancer. *Nat Rev Clin Oncol*. 2010; 7: 508-19 [Review]
14. **Banerjee S** and Cunningham D (2010) Targeted therapies as adjuvant treatment for early stage colorectal cancer: first impressions and clinical questions. *Clinical Colorectal Cancer*. 2010; 9, Suppl. 1, S28-S35 [Review]
13. **Banerjee S**, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, Martin LA. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. *Clin Cancer Res*. 2010; 16: 4178-87
12. Smith IE, **Banerjee S**. The follow-up of women at high risk for breast cancer relapse. *Breast*. 2009; 18 Suppl 3: S74-7 [Review]

11. **Banerjee S**, Gore M. The future of targeted therapies in ovarian cancer. *Oncologist*. 2009; 14: 706-16 [Review]
10. **Banerjee S**, Zvelebil M, Furet P, Mueller-Vieira U, Evans DB, Dowsett M, Martin LA. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. *Cancer Res*. 2009; 69: 4716-23
9. **Banerjee S**, Pancholi S, A'Hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. *Clin Cancer Res*. 2008; 14: 2656-63
8. Pancholi S, Lykkesfeldt AE, Hilmi C, **Banerjee S**, Leary A, Drury S, Johnston S, Dowsett M, Martin LA. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. *Endocr Relat Cancer*. 2008; 15: 985-1002
7. **Banerjee S**, Gore M. Targeted Therapies for the Management of Gynaecological Cancers. Royal College of Obstetrics and Gynaecology Scientific Opinion Paper, 2008; no. 12 [Review]
6. **Banerjee S**, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. *Nat Clin Pract Oncol*. 2007; 4: 536-50 [Review]
5. **Banerjee S**, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. *J Clin Pathol*. 2006; 59: 729-35
4. **Banerjee S**, Smith IE, Folklerd L, Iqbal J, Barker P, Dowsett M. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. *Ann Oncol* 2005; 16: 1632-8
3. Lee J, **Banerjee S** and King M. Breast or chest – A diagnostic conundrum. *Br J Radiol*. 2005; 78: 471-472
2. **Banerjee S** and Smith I. A patient with estrogen receptor-positive breast cancer treated with neoadjuvant anastrozole. *Case Studies in Breast Cancer*. 2004; 3; 12.
1. **Banerjee SN**, Watkinson T, Greenbaum R. Coronary artery rupture treated with microcoil occlusion. *Heart*. 2001; 86: 187

Other articles (author reply)

- †**Banerjee S**. Reply to 'Physician burnout:let's avoid unsubstantiated claims'. *Nat Rev Clin Oncol*. 2018 Dec 18. doi: 10.1038/s41571-018-0151-7
- †**Banerjee S**, Preusser M, Taberner J, Strijbos M. Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al. *Ann Oncol*. 2017 Oct 1;28(10):2625-2626.

Book Chapters/Editions

J Stewart, S **Banerjee**, D Lorusso and E Tripodi. ESMO Handbook of Immuno-Oncology. Gynaecological Cancers. 2018

Emily Grist, Lucy Dumas, Jacqueline Gilbert, **Susana Banerjee**. Advanced Ovarian Cancer in a Patient who Is Socially Isolated and Deaf. Ring A, Harari D, Kalsi T, Mansi J, Selby P, editors. Problem Solving in Older Cancer Patients. 1st ed. Oxford: Clinical Publishing; 2016. Bibliog: 978-1-84692-110-0; 328 pp; 234 x 156mm; Illustrations; Paperback

Cristiana Sessa, Giampaolo Tortora, Aldo Scarpa, **Susana Banerjee**. ESMO Handbook on Translational Research. Co-Editor 2016.

Rafii, Kaye and **Banerjee S**. Current status and future direction of PARP inhibition in cancer therapy. Targeted Therapy in Translational Cancer Research (eds A.-M. Tsimberidou, R. Kurzrock and K. C. Anderson), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118468678.ch33

Khakoo and **Banerjee S**. Neoadjuvant and Adjuvant Chemotherapy for Advanced Ovarian Cancer, Including Biological Agents. Pelvic Surgery. Springer, pp.441-453

George and **Banerjee S**. The role of breast cancer genes in gynaecological cancers. Recent Advances in Obstetrics and Gynaecology. Edited by William Ledger, Justin Clar

Banerjee S (2011). Novel Treatment Strategies for Targeting Genetic Changes in Endometrial Cancer. Gynaecological Cancers: Biology and Therapeutics. Edited by Sean Kehoe, Richard J Edmondson, Martin Gore and Iain A McNeish. RCOG